To view or add a comment, sign in GLP-1 weight-loss drugs are changing how people eat, with AHDB research showing lower volumes but stronger demand for high-quality red meat
Many drugs look promising in cells, mice, or tissue samples but fail in later stages because: The treatment doesnt work well enough in humans It causes side effects at real doses The effect fades over time The human joint environment is much more complex than the lab So while we are hopeful, there is a long road ahead before this approach could become a real treatment
Structural rebuilding depends on: Adequate blood flow so repair materials can reach the site Proper cellular migration so rebuilding is organized Inflammation control so tissue is not continually degraded When GHK-Cu is used alone, you may see improvements in texture and appearance, yet deeper functional recovery can lag when the rest of the repair system is not supported
[38] [39] It enables the interconversion of cyano- and alkylcobalamins
The timing concern is purely mechanical, related to gastric emptying rate and pH exposure